Investigation of galectin-3 levels in diabetic foot ulcers
Authors:
- 2 December 2018
- journal article
- research article
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 27 (12) , 843-848
Abstract
Objective: It has been shown that galectin-3 (Gal-3) promotes angiogenesis and new vessel formation. Serum Gal-3 is a risk factor for vascular complications in type 2 diabetes. The aim of this study is to compare Gal-3 levels with a range of biochemical parameters.Method: A prospective study consisted of individuals as a control group (group 1), patients diagnosed with type 2 diabetes without DFUs (group 2), and patients with type 2 diabetes with a DFU (group 3). Patient levels of endothelin-1 (ET-1), vascular endothelial growth factor-A (VEGF-A), nitric oxide (NO), and Gal-3 were measured.Results: In total, 91 patients participated, (28 male, 63 female with a mean age of 55.83±6.35 years) Mean ET-1 (39.0±16.9), NO (17.6±7.6), VEGF-A (33.5±13.4) and Gal-3 (535.1±420.5) levels were significantly higher in group 3 compared with the other two groups (p<0.01). Furthermore, the Gal-3 level was positively and statistically significantly correlated with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ET-1 and NO levels in all groups.Conclusion: In our study, the level of Gal-3 was shown to be positively correlated with the VEGF-A level. Hence, Gal-3 can be considered as a defence mechanism against complications of diabetes, thus contributing to wound healing. Gal-3 may play a critical role in DFU formation and progression. Moreover, it could be suggested that Gal-3 may give an indication of prognosis, as it elevates VEGF-A levels and stimulates angiogenesis. Further studies are required to confirm the findings of this study.Keywords
This publication has 26 references indexed in Scilit:
- Galectin-3 Mediates Aldosterone-Induced Vascular FibrosisArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- The fibrosis marker galectin‐3 and outcome in the general populationJournal of Internal Medicine, 2011
- The costs of diabetic foot: The economic case for the limb salvage teamJournal of Vascular Surgery, 2010
- Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic miceGenetic Vaccines and Therapy, 2010
- Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic responseJournal of Experimental Medicine, 2010
- Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophilsGlycobiology, 2008
- Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte ChemoattractionArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal FibrosisThe American Journal of Pathology, 2008
- Galectin-3 Gene Inactivation Reduces Atherosclerotic Lesions and Adventitial Inflammation in ApoE-Deficient MiceThe American Journal of Pathology, 2008
- Galectin-3: An open-ended storyBiochimica et Biophysica Acta (BBA) - General Subjects, 2006